F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy. This story matters for General News readers tracking general. Reported by nytimes.com. Read the full original at the source link below.
Originally reported by nytimes.com. NewsDebate curates and briefs the general news stories that matter. Our editorial policy →